Irofulven in Treating Patients With Metastatic Breast Cancer

NCT00003796 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

NIH

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: irofulven

Sponsor

National Cancer Institute (NCI)